Edition:
United States

GlycoMimetics Inc (GLYC.OQ)

GLYC.OQ on NASDAQ Stock Exchange Global Market

17.52USD
3:42pm EDT
Change (% chg)

$0.21 (+1.21%)
Prev Close
$17.31
Open
$17.34
Day's High
$17.55
Day's Low
$17.16
Volume
48,717
Avg. Vol
259,602
52-wk High
$26.05
52-wk Low
$3.83

Latest Key Developments (Source: Significant Developments)

Glycomimetics Announces Pricing Of Public Offering Of Common Stock
Tuesday, 20 Mar 2018 09:24pm EDT 

March 20 (Reuters) - Glycomimetics Inc ::GLYCOMIMETICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 7.00 MILLION COMMON SHARES PRICED AT $17.00PER SHARE.  Full Article

GlycoMimetics Announces Proposed Public Offering Of Common Stock
Monday, 19 Mar 2018 04:01pm EDT 

March 19 (Reuters) - Glycomimetics Inc ::GLYCOMIMETICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.GLYCOMIMETICS INC - ‍INTENDS TO OFFER AND SELL, SUBJECT TO MARKET CONDITIONS, 4.5 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING​.GLYCOMIMETICS -TO USE PROCEEDS OF OFFERING TO CONDUCT PHASE 3 CLINICAL DEVELOPMENT PROGRAM FOR GMI-1271 IN PATIENTS WITH ACUTE MYELOID LEUKEMIA​.GLYCOMIMETICS - TO USE NET PROCEEDS OF OFFERING TO CONDUCT, COMPLETE ITS PLANNED PHASE 3 CLINICAL DEVELOPMENT PROGRAM FOR GMI-1271.  Full Article

Glycomimetics Reports Q4 Loss Per Share $0.27
Tuesday, 6 Mar 2018 07:30am EST 

March 6 (Reuters) - Glycomimetics Inc ::GLYCOMIMETICS REPORTS FOURTH QUARTER AND YEAR-END 2017 RESULTS.GLYCOMIMETICS INC QUARTERLY LOSS PER SHARE $0.27.GLYCOMIMETICS INC - AS OF DEC 31, 2017, HAD CASH AND CASH EQUIVALENTS OF $123.9 MILLION AS COMPARED TO $40.0 MILLION AS OF DECEMBER 31, 2016.  Full Article

Glycomimetics Announces Design Of Phase 3 Clinical Trial For GMI-1271
Monday, 5 Mar 2018 04:01pm EST 

March 5 (Reuters) - Glycomimetics Inc ::GLYCOMIMETICS ANNOUNCES DESIGN OF PHASE 3 CLINICAL TRIAL FOR GMI-1271 IN RELAPSED/REFRACTORY AML.GLYCOMIMETICS INC - PRIMARY ENDPOINT FOR SINGLE PIVOTAL CLINICAL TRIAL WILL BE OVERALL SURVIVAL.GLYCOMIMETICS INC - MULTIPLE CLINICAL READOUTS PLANNED STARTING YEAR-END 2018 AND THROUGH 2019 AND 2020.GLYCOMIMETICS INC - IN EARLY 2019, ANTICIPATE TOPLINE DATA FROM PROOF-OF-CONCEPT TRIAL OF GMI-1271 IN MULTIPLE MYELOMA.  Full Article

Glycomimetics Enters Agreement With Hovon To Initiate Study Startup Activities For Planned Clinical Trial Of GMI-1271 And Decitabine
Thursday, 8 Feb 2018 09:00am EST 

Feb 8 (Reuters) - Glycomimetics Inc ::GLYCOMIMETICS ENTERS INTO AGREEMENT WITH HOVON TO INITIATE STUDY STARTUP ACTIVITIES FOR PLANNED CLINICAL TRIAL OF GMI-1271 AND DECITABINE IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE UNFIT FOR CHEMOTHERAPY.GLYCOMIMETICS INC - ‍ON TRACK TO DISCLOSE DETAILS FOR DESIGN OF PHASE 3 TRIAL IN RELAPSED/REFRACTORY AML PATIENTS DURING 2017 YEAR-END EARNINGS CALL.GLYCOMIMETICS INC - ‍ HOVON INTENDS TO ENROLL APPROXIMATELY 140 PATIENTS IN CLINICAL TRIAL OF GMI-1271 AND DECITABINE​.  Full Article

GlycoMimetics qtrly loss per share $‍0.24
Wednesday, 8 Nov 2017 07:30am EST 

Nov 8 (Reuters) - Glycomimetics Inc :Glycomimetics reports program updates and third quarter 2017 results.Glycomimetics inc - ‍phase 3 clinical trial of rivipansel on track for completion in second half of 2018​.Glycomimetics inc qtrly loss per share $‍0.24​.Glycomimetics inc - ‍research and development expenses decreased slightly to $5.8 million for quarter ended september 30, 2017 as compared to $5.9 million​.  Full Article

GlycoMimetics says files for mixed shelf of upto $250 mln
Thursday, 28 Sep 2017 05:59pm EDT 

Sept 28 (Reuters) - GlycoMimetics Inc :GlycoMimetics Inc says files for mixed shelf of upto $250.0 million - SEC filing‍​.  Full Article

Glycomimetics presents updated data from ongoing phase 1/2 clinical trial of GMI-1271 at ASCO
Monday, 5 Jun 2017 07:00am EDT 

June 5 (Reuters) - Glycomimetics Inc :Glycomimetics presents updated data from ongoing phase 1/2 clinical trial of GMI-1271 in patients with acute myeloid leukemia at ASCO 2017 annual meeting.Glycomimetics Inc says GMI-1271 continues to be well tolerated in combination with induction chemotherapy.Glycomimetics -remission rates continue to be higher than historical controls & induction-related mortality continues to be lower than historical controls.Glycomimetics Inc - in study only one case of severe (grade 3/4) mucositis reported among 79 patients receiving high-intensity induction chemotherapy.Glycomimetics Inc - relapsed/refractory patients with more blasts expressing e-selectin ligand were more likely to achieve complete response in study.  Full Article

Glycomimetics announces pricing of public offering of common stock
Wednesday, 24 May 2017 08:00am EDT 

May 24 (Reuters) - Glycomimetics Inc :Glycomimetics announces pricing of public offering of common stock.Says public offering of 7.00 million common shares priced at $11.50per share.  Full Article

Glycomimetics Inc terminates sales agreement with Cowen and Company
Wednesday, 24 May 2017 07:25am EDT 

May 24 (Reuters) - Glycomimetics Inc :Glycomimetics Inc - co terminated its sales agreement, dated March 1, 2016, with Cowen and Company.  Full Article